James Wilson, MD
Neurology · Milledgeville, GANPI 1144398140
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $527 and has fallen 78.7% since, to $112 in 2025. That places this record below the midpoint for neurology clinicians in GA, where the typical reported total is $1,471.
Across 100 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$314
- UCB, Inc.$146
- Lilly USA, LLC$115
- Teva Pharmaceuticals USA, Inc.$98
- AbbVie$91
- SK Life Science, Inc.$80
- plus $679 from 19 others
What the payments were for
- Food & beverage$1,48497%
- Education$393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 34 | $314 |
| UCB, Inc. | 7 | $146 |
| Lilly USA, LLC | 6 | $115 |
| Teva Pharmaceuticals USA, Inc. | 6 | $98 |
| AbbVie(2 entities) | 5 | $91 |
| SK Life Science, Inc. | 3 | $80 |
| Eisai Inc. | 5 | $68 |
| AstraZeneca | 3 | $62 |
| Biogen | 4 | $56 |
| EMD Serono, Inc. | 3 | $46 |
| Neurocrine Biosciences, Inc. | 3 | $46 |
| Catalyst Pharmaceuticals, Inc. | 1 | $46 |
| Tanabe Pharma America, Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Pfizer | 2 | $37 |
| Novartis | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $30 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Adamas Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$1,523 in reported general payments places this provider in the 50th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FycompaPerampanel | 28 | $35,102 |
| Nurtec OdtRimegepant Sulfate | 16 | $32,808 |
| QuliptaAtogepant | 21 | $31,101 |
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $25,160 |
| Emgality PenGalcanezumab-Gnlm | 28 | $19,595 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $17,170 |
| Lacosamide | 143 | $15,049 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 228 | $12,266 |
| Levetiracetam | 271 | $11,931 |
| Rasagiline Mesylate | 20 | $7,612 |
| Primidone | 91 | $5,138 |
| Divalproex Sodium ErDivalproex Sodium | 64 | $4,723 |
| Mycophenolate Mofetil | 21 | $4,114 |
| Lamotrigine | 135 | $3,020 |
| Pyridostigmine Bromide | 24 | $2,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Fycompa | $68 | $35,10228 claims |
| PfizerNurtec Odt | $37 | $32,80816 claims |
| AbbVieQulipta | $91 | $31,10121 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $33 | $25,16016 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide | $17 | $6,72945 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 506 neurology providers in Georgia.
Other neurology in Milledgeville
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Dinesh RajuLawrenceville$414K
- Victor RosenfeldSavannah$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.